<DOC>
	<DOC>NCT00366249</DOC>
	<brief_summary>The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.</brief_summary>
	<brief_title>Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Osteomyelitis</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Main inclusion criteria: Men and women aged 18 or older with diabetes and a qualifying foot infection. People with evidence of a diabetic foot infection with osteomyelitis may qualify for the osteomyelitis substudy arm. Main exclusion criteria: People with additional significant disease, infection with resistant pathogens, contraindication, or hypersensitivity to any test article or related antibiotic.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Diabetic foot infection</keyword>
	<keyword>Osteomyelitis</keyword>
	<keyword>Diabetes Complications</keyword>
	<keyword>Foot ulcer</keyword>
	<keyword>Skin infection</keyword>
</DOC>